Organic compounds -- part of the class 532-570 series – Organic compounds – Carbohydrates or derivatives
Reexamination Certificate
2005-10-05
2010-10-05
Helms, Larry R. (Department: 1643)
Organic compounds -- part of the class 532-570 series
Organic compounds
Carbohydrates or derivatives
C435S455000
Reexamination Certificate
active
07807804
ABSTRACT:
Nucleic acid molecules modified to enhance recombinant protein, e.g., antibody, expression and/or reduce or eliminate mis-spliced and/or intron read-through (IRT) by-products are disclosed. The invention also provides methods for producing proteins devoid of mis-spliced and/or intron read-through by-products by the use of such vectors in host cells under cell culture conditions suitable for recombinant protein expression.
REFERENCES:
patent: 6075181 (2000-06-01), Kucherlapati et al.
patent: 6150141 (2000-11-01), Jarrell
patent: 7122637 (2006-10-01), Presta
patent: 2003/0165496 (2003-09-01), Basi et al.
patent: WO 87/02671 (1987-05-01), None
patent: WO 2005/035753 (2005-04-01), None
patent: 2006041934 (2006-04-01), None
Choi T et al., “A Generic Intron Increases Gene Expression in Transgenic Mice”,Molecular and Cellular Biology, vol. 11, No. 6:pp. 3070-3074 (1991).
Robbins P F et al., “The Intronic Region of an Incompletely Spliced gp100 Gene Transcript Encodes an Epitope Recognized by Melanoma-Reactive Tumor-Infiltrating Lymphocytes”,Journal of Immunology, vol. 159, No. 1:pp. 303-308 (1997).
Ward S B et al., “Spontaneous deletions in Ig heavy chain genes: flanking sequences influence splice site selection”,Nucleic Acids Research, vol. 19, No. 23:pp. 6475-6480 (1991).
Myers K A et al., “Targeting immune effector molecules to human tumor cells through genetic delivery of 5T4-specific scFv fusion proteins”Cancer Gene Therapy, vol. 9, No. 11:pp. 884-896 (2002).
Neuberger M S et al., “The intron requirement for immunoglobulin gene expression is dependent upon the promoter”,Nucleic Acids Research, vol. 16, No. 14:pp. 6713-6724 (1988).
Buchman A R et al., “Comparison of Intron-Dependent and Intron-Independent Gene Expression”Molecular and Cellular Biology, vol. 8, No. 10:pp. 4395-4405 (1988).
Nott A et al., “A quantitative analysis of intron effects on mammalian gene expression”,RNA, vol. 9:pp. 607-617 (2003).
“Nucleotide sequence of a variable heavy chain of IgG4”,Geneseq Database Accession No. ADZ51216, 2 pages (Jun. 30, 2005).
Bourdon V et al., “Introns and their positions affect the transation activity of mRNA in plant cells”,EMBO Reports, vol. 2, No.5 pp. 394-398 (2001).
International Search Report in corresponding International Application PCT/US05/35854, dated Feb. 19, 2009.
DD149398, “Bispecific antibody having the ability of substitution for functional protein”, EMBL Record dated Nov. 9, 2005, (EMBL [online] Hinxton, Cambridge, UK), EMBL Nucleotide Sequence Submissions, retrieved from EBI accession No. EMBL:DD149398, Database accession No. DD149398.
ACC47228, “Hu266 N56T heavy chain encoding DNA”, Geneseq Record dated Aug. 18, 2003, (Geneseq [online] New York, NY, US), Science Geneseq, retrieved from EBI accession No. GSN:ACC47228, Database accession No. ACC47228.
Laken Haley A.
Leonard Mark
Rouse Jason
Sinacore Martin S.
Helms Larry R.
Lando & Anastasi LLP
Natarajan Meera
Wyeth LLC
LandOfFree
Methods and compositions for improving recombinant protein... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods and compositions for improving recombinant protein..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods and compositions for improving recombinant protein... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4155010